靶向谷氨酰胺和PD1抑制剂在肝癌中的研究进展-现代医学

靶向谷氨酰胺和PD1抑制剂在肝癌中的研究进展

单位：武汉科技大学附属天佑医院肿瘤科, 湖北武汉 430064

分类号：R7

出版年·卷·期（页码）：2022·50·第八期（1077-1081）

摘要：

近年来，肿瘤代谢成为研究热点，其机制目前认为与代谢重编程，即“Warburg效应”有关。代谢重编程通过改变肿瘤微环境中代谢物质水平从而激活相关传导通路，调控细胞基因表达，促进肿瘤细胞增殖。如谷氨酰胺可通过Wnt/β-连环蛋白等途径调控肝癌PD-1/PD-L1的表达和促进肝癌的生长，所以谷氨酰胺代谢成为肝癌治疗的新靶点。目前研究结果显示单一谷氨酰胺抑制剂或免疫抑制剂治疗效果有限，因此靶向谷氨酰胺联合PD-1/PD-L1抑制剂可能成为肝癌治疗的选择方案。

Hepatocellular carcinoma (HCC) ranks fifth in the global cancer morbidity,and the recurrence rate within 2 years is as high as 50%.In recent years,tumour metabolism has become a hotspot,to which more and more researchers have paid attention.Its mechanism is currently considered to be related to metabolic reprogramming,namely "Warburg effect",and associated with glutamine metabolism.Metabolic reprogramming activates certain metabolic pathway by changing the level of metabolic substances in the tumor microenvironment,then regulates gene expression and accelerates the proliferation of tumor cells.For example glutamine can promote the growth of liver cancer and regulate the expression of PD-1/PD-L1 through the Wnt/β-catenin pathway,so it may be a new therapeutic target for hepatocellular carcinoma.Currently research results have shown that single glutamine inhibitors or immune checkpoint inhibitors have limited therapeutic effect.Therefor,targeted glutamine combined with PD-1/PD-L1 inhibitors may become an available therapeutic schedule for HCC.

参考文献：

[1] PRIETO J,MELERO I,SANGRO B.Immunological landscape and immunotherapy of hepatocellular carcinoma[J].Nat Rev GastroenterolHepatol,2015,12(12):681-700.
[2] 周雪峰.谷氨酰胺与肿瘤免疫、化学治疗、放射治疗[J].国外医学外科学,2002,29(6):334-336.
[3] OH M H,SUN I H,ZHAO L,et al.Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells[J].The Journal of Clinical Investigation,2020,130(7):3865-3884.
[4] GETTINGER S N,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody,BMS-936558,ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J].Journal of Clinical Oncology,2015,33(18):2004-2012.
[5] RIZVI N A,MAZIōRES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].The Lancet Oncology,2015,16(3):257-265.
[6] 刘宇佳,张轶雯,钟里科,等.肿瘤微环境对肿瘤代谢的影响及研究进展[J].肿瘤学杂志,2020,26(1):47-52.
[7] ATREYA C E,TURNBAUGH P J.Probing the tumor micro (b) environment[J].Science,2020,368(6494):938-939.
[8] 李佳颖,胡雨婷.代谢重编程与近端肾小管损伤的研究进展[J].中华肾脏病杂志,2020,36(11):892-896.
[9] 姚利昂,胡泽平.瘤代谢重编程与药物耐药性[J].中国医学前沿杂志,2019,11(2):23-27.
[10] PAWLIK T M,SOUBA W W,SWEENEY T J,et al.Amino acid uptake and regulation in multicellular hepatoma spheroids[J].Journal of Surgical Research,2000,91(1):15-25.
[11] TAO J,ZHANG R,SINGH S,et al.Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice[J].Hepatology,2017,65(5):1581-1599.
[12] CIEPLY B,ZENG G,PROVERBS-SINGH T,et al.Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene[J].Hepatology,2009,49(3):821-831.
[13] REBOUISSOU S,FRANCONI A,CALDERARO J,et al.Genotype-phenotype correlation of CTNNB1 mutations reveals different β-catenin activity associated with liver tumor progression[J].Hepatology,2016,64(6):2047-2061.
[14] LIU P,LU D,AL-AMERI A,et al.Glutamine synthetase promotes tumor invasion in hepatocellular carcinoma through mediating epithelial-mesenchymal transition[J].Hepatology Research,2020,50(2):246-257.
[15] 梁宝瑜,金春,高俪原,等.谷氨酰胺转运蛋白ASCT2的研究进展[J].中国药理学通报,2020,36(1):22-25.
[16] BAR-PELED L,SABATINI D M.Regulation of mTORC1 by amino acids[J].Trends in Cell Biology,2014,24(7):400-406.
[17] BOND P.Regulation of mTORC1 by growth factors,energy status,amino acids and mechanical stimuli at a glance[J].Journal of the International Society of Sports Nutrition,2016,13(1):1-11.
[18] ZHANG M,FU Y,CHEN Y,et al.Inhibition of the mTORC1/NF-κB axis alters amino acid metabolism in human hepatocytes[J].BioMed Research International,2021,2021:862146.
[19] 万燕萍.谷氨酰胺对人肝癌细胞系SMMC-7721增殖影响的体外研究[J].胃肠病学,2005,10(3):148-152.
[20] ZHONG X,LI W,HUANG X,et al.Effects of glutamine supplementation on the immune status in weaning piglets with intrauterine growth retardation[J].Archives of Animal Nutrition,2012,66(5):347-356.
[21] DIETL K,RENNER K,DETTMER K,et al.Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes[J].The Journal of Immunology,2010,184(3):1200-1209.
[22] PALSSON-MCDERMOTT E M,CURTIS A M,Goel G,et al.Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages[J].Cell Metabolism,2015,21(1):65-80.
[23] WEI H R,GAO P.Regulation of cancer cell metabolism[J].Scientia Sinica Vitae,2017,47(1):132-139.
[24] PALSSON-MCDERMOTT E M,DYCK L,ZASLONA Z,et al.Pyruvate kinase M2 is required for the expression of the immune checkpoint PD-L1 in immune cells and tumors[J].Frontiers in Immunology,2017,8:1300.
[25] EL-ANSARI R,CRAZE M L,ALTHOBITI M,et al.Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer[J].British Journal of Cancer,2020,122(1):94-101.
[26] MA G,IANG Y,CHEN Y,et al.Glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-Jun signaling in renal cancer[J].Molecular Cancer Research,2020,18(2):324-339.
[27] CHEN N,FANG W,ZHANG J,et al.Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC:implication for optional immune targeted therapy for NSCLC patients with EGFR mutation[J].Journal of Thoracic Oncology,2015,10(6):910-923.
[28] INAMURA K,YOKOUCHI Y,SAKAKIBARA R,et al.Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma[J].Japanese Journal of Clinical Oncology,2016,46(10):935-941.
[29] WANG L,YANG X,LI D,et al.The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon-γ[J].OncoTargets and Therapy,2018,11:7229-7243.
[30] JIN H,WANG S,ZAAL E A,et al.A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer[J].Elife,2020,9:e56749.
[31] DAI W,XU L,YU X,et al.OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism[J].Journal of Hepatology,2020,72(5):909-923.
[32] LEONE R D,ZHAO L,ENGLERT J M,et al.Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion[J].Science,2019,366(6468):1013-1021.
[33] SHARMA N S,GUPTA V K,GARRIDO V T,et al.Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy[J].The Journal of Clinical Investigation,2020,130(1):451-465.
[34] MASSARD C,GORDON M S,SHARMAS,et al.Safety and efficacy of durvalumab (MEDI4736),an anti-programmed cell death ligand-1 immune checkpoint inhibitor,in patients with advanced urothelial bladder cancer[J].Journal of Clinical Oncology,2016,34(26):3119.
[35] EL-KHOUEIRY A B,YAU T,KANG Y K,et al.Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC):long-term results from CheckMate 040[J].Journal of Clinical Oncology,2021,39(3):269.
[36] MERLE P,EDELINE J,BOUATTOUR M,et al.Pembrolizumab (pembro)vs. placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib:updated data from the randomized,phase Ⅲ KEYNOTE-240 study[J].Journal of Clinical Oncology,2021,39(3):268.
[37] BYUN J K,PARK M,LEE S,et al.Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity[J].Molecular Cell,2020,80(4):592-606.
[38] VARGHESE S,PRAMANIK S,WILLIAMS L J,et al.The glutaminase inhibitor CB-839(Telaglenastat) enhances the antimelanoma activity of T-Cell-Mediated immunotherapies[J].Mol Cancer Ther,2021,20(3):500-511.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录